OakChart

Picard Medical Inc

PMIHealthcare·Medical Devices·USA·Nano·AMEX·Nov 11 • 3:59 PM ET

8.04-0.01 (-0.12%)
2026-11-12 01:03 CET
Market cap
19.79 USD m
Revenue, TTM
6.30 USD m
Net income, TTM
-27.99 USD m
Free cash flow, TTM
-16.07 USD m
EPS diluted, TTM
-20.65
P/E
-
Compare

Price

PMI against its 20, 50 and 200-day averages
2050200earnings
0.0050.00100.00150.0020.8M41.6MVolumeApr 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PMIclose 8.0420-day 8.7350-day 7.32200-day 27.278.04

96.1% under the 52-week high of 208.00 on 4 Dec 2025. 52-week low 2.65 on 21 Aug 2026. Last 15 sessions, 48.9% high to low

Volume 0.01× normal · the line is the 50-bar volume average

Profile

PMI
52-week range, 3% of the way up
2.65208

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Employees75
IPOAug 29, 2025
Beta-2.72
ATR, 14d1.64
Rel volume0.01
Short float5.03%
Insider own39.84%
Inst own5.99%

Snapshot

6 groups

Valuation

Index-
Market Cap19.77M
Enterprise Value21.31M
Income-27.99M
Sales6.30M
Book/sh0.83
Cash/sh0.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees75
IPOAug 29, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S3.14
P/B9.63
P/C494.14
P/FCF-
EV/EBITDA-
EV/Sales3.38
Quick Ratio0.22
Current Ratio1.02
Debt/Eq0.92
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-20.65
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-27.88% -
Sales past 3/5Y6.30% -
EPS Y/Y TTM0.82%
Sales Y/Y TTM41.00%
EPS Q/Q40.21%
Sales Q/Q38.62%
EarningsAug 20 BMO
EPS/Sales Surpr.-103.33% 90.58%

Ownership

Insider Own39.84%
Insider Trans0.00%
Inst Own5.99%
Inst Trans10.05%
ROA-268.26%
ROE-
ROIC-1631.29%
Gross Margin17.90%
Oper. Margin-248.10%
Profit Margin-444.33%
SMA20-7.93%
SMA509.82%
SMA200-70.52%
Trades-

Technical

Shs Outstand2.06M
Shs Float1.48M
Short Float5.03%
Short Ratio0.05
Short Interest0.07M
52W High208.00 -96.13%
52W Low2.65 203.17%
Volatility14.03% 26.68%
ATR (14)1.64
RSI (14)49.25
Beta-2.72
Rel Volume0.01
Avg Volume1.60M
Volume16,628

Performance

Perf Week11.82%
Perf Month-47.55%
Perf Quarter129.06%
Perf Half Y1.71%
Perf YTD-90.81%
Perf Year-94.40%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close8.05
Price8.04
Change %-0.12%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
May 18, 2026InitiatedHH.C. WainwrightNeutral

Peers

Mkt cap
TickerCompanyMkt cap
AORTArtivion Inc980.68M
TMDXTransmedics Group Inc3.20B
CVRXCVRx Inc19.95M
AVRAnteris Technologies Global Corp604.46M
EWEdwards Lifesciences Corp60.84B
NUWENuwellis Inc2.99M
NSPRInspireMD Inc37.19M
NVNOenVVeno Medical Corp4.53M
ADGMAdagio Medical Holdings Inc1.71M
HSCSHeartSciences Inc11.40M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Sindex SSI Lending, LLC10% OwnerJun 03 '26Proposed Sale0.323,971,7931,259,853Jun 03 04:03 PM
Sindex SSI Lending, LLC10% OwnerJun 01 '26Proposed Sale0.183,971,793695,064Jun 01 05:36 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B

News

latest 14 of 128
  • Picard Medical Shares Soar After Quarterly Revenue Beats Forecasts (InvestorsHub) +59.81%
  • Picard Medical Reports Second Quarter 2026 Financial Results (GlobeNewswire) -7.90%
  • Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026 (GlobeNewswire)
  • Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026 (GlobeNewswire)
  • Picard Medical Receives NYSE American Acceptance of Compliance Plan (GlobeNewswire)
  • Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance (GlobeNewswire) -27.06%
  • Artificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program (GlobeNewswire) +7.29% +6.52%
  • Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting (GlobeNewswire) -7.47%
  • Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting (GlobeNewswire)
  • Picard Medical Announces Leadership Transition (GlobeNewswire)
  • Picard Medical and SynCardia to Present New In Vivo Emperor Total Artificial Heart Data and Patient Outcome Research at ASAIO 2026 (GlobeNewswire)
  • Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies (GlobeNewswire) +60.33%
  • PICARD MEDICAL, INC. Issues Letter to Shareholders (GlobeNewswire)
  • Picard Medical / SynCardia Reports First Quarter 2026 Financial Results (GlobeNewswire) -8.44%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-20-3.050-1.500-2.951.551
2026Q12026-05-21-5.000-5.000-5.1161.151.151
2025Q42026-02-25-3.000--2.9111.01--
2025Q32025-11-14---1.19--
2026Q3---1.500--1.551
2026Q4---1.500--1.251
2027Q1---1.500--1.201
2027Q2---1.000--1.801
2027Q3---1.000--1.801
2027Q4---1.000--1.301

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-37.500--4.94-
2026FY--8.500--5.50
2027FY--4.500--5.90

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-201001.551.551.55
2026Q3S2026-05-211001.551.551.55
2026Q3S2026-05-151001.551.551.55
2026Q3E2026-08-20100-1.50-1.50-1.50
2026Q3E2026-05-21100-1.50-1.50-1.50
2026Q3E2026-05-15100-1.50-1.50-1.50
2026Q2S2026-05-211001.551.551.55
2026Q2S2026-05-151001.551.551.55
2026Q2E2026-05-21100-1.50-1.50-1.50
2026Q2E2026-05-15100-1.50-1.50-1.50
2026Q1S2026-05-151001.151.151.15
2026Q1E2026-05-15100-0.10-0.10-0.10
2026FYS2026-05-151005.505.505.50
2026FYE2026-05-15100-8.50-8.50-8.50

Estimate history

EPS, annual-8.759-243.892-16.41-18.319-20.65
Period2022202320242025TTM
EPS, quarterly-3.264-4.763-6.574-4.384-5.102-9.574-2.911-5.116-3.05
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual4.1135.0434.3914.946.3
Period2022202320242025TTM
Sales, quarterly0.6940.8810.8360.622.1311.1871.0091.152.954
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual1.4460.0741.4461.4742.055
Period2022202320242025MRQ
Shares, quarterly1.4461.4461.4461.4461.4741.4741.4741.5052.055
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue6.304.944.395.044.11
Cost of Goods Sold Incl. D&A5.175.194.507.359.10
Gross Profit1.13-0.25-0.11-2.31-4.99
Selling, General and Administrative Excl. Other16.7613.0013.6013.196.08
Research and Development4.773.053.382.211.90
Other Operating Expense0.000.000.000.000.00
Operating Income-15.63-13.26-13.71-15.50-11.07
Interest Expense4.807.693.070.140.01
Unusual Expense7.576.024.290.000.00
Net Income Before Taxes-27.98-26.97-21.07-15.57-11.16
Income Taxes0.010.04-0.01-0.000.01
Consolidated Net Income-27.99-27.00-21.05-15.57-11.17
Net Income From Continuing Operations-27.99-27.00-21.05-15.57-11.17
Net Income-27.99-27.00-23.74-18.00-12.67
EPS (Recurring)-12.23-15.46-14.33-243.89-8.76
EPS (Basic, Before Extraordinaries)-20.65-18.32-16.41-243.89-8.76
EPS (Diluted)-20.65-18.32-16.41-243.89-8.76
EBITDA-15.10-12.74-13.17-14.92-10.52
Non-Operating Income (Expense)0.010.000.000.07-0.09
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense1.590.600.700.110.12
Price To Sales Ratio2.4126.11---
Gross Margin17.90-5.12-2.55-45.83-121.27
Operating Margin-248.10-268.36-312.28-307.40-269.07
Net Margin-444.33-546.60-540.58-356.97-308.05
Shares Outstanding2.061.471.450.071.45
Market Capitalization19.7919.79128.98--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue2.951.151.011.192.130.620.840.88
Cost of Goods Sold Incl. D&A2.340.900.601.332.280.980.701.55
Gross Profit0.620.250.41-0.15-0.15-0.360.14-0.67
Selling, General and Administrative Excl. Other5.254.763.413.343.372.893.713.77
Research and Development1.371.900.550.950.740.810.790.96
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.63-4.51-3.00-3.49-3.52-3.25-3.57-4.44
Interest Expense0.090.012.302.402.430.561.431.38
Unusual Expense0.953.10-1.024.540.781.733.850.38
Net Income Before Taxes-5.65-7.62-4.29-10.43-6.72-5.53-8.85-6.21
Income Taxes0.010.000.000.000.000.03-0.010.00
Consolidated Net Income-5.66-7.62-4.29-10.43-6.72-5.56-8.84-6.21
Net Income From Continuing Operations-5.66-7.62-4.29-10.43-6.72-5.56-8.84-6.21
Net Income-5.66-7.62-4.29-10.43-7.52-6.34-9.51-6.89
EPS (Recurring)-2.69-3.66-3.39-6.66-4.73-3.55-4.71-4.58
EPS (Basic, Before Extraordinaries)-3.05-5.12-2.91-9.57-5.10-4.38-6.57-4.76
EPS (Diluted)-3.05-5.12-2.91-9.57-5.10-4.38-6.57-4.76
EBITDA-4.50-4.37-2.87-3.36-3.40-3.12-3.44-4.32
Non-Operating Income (Expense)0.010.000.000.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.090.170.180.160.180.110.18-
Price To Sales Ratio2.4114.1326.0796.95----
Gross Margin20.8521.6540.73-12.47-6.90-57.7416.27-76.39
Operating Margin-156.70-392.26-297.62-293.77-165.23-523.55-427.27-504.43
Net Margin-191.60-662.26-425.27-878.35-352.89-1,022.74-1,137.44-781.95
Shares Outstanding2.061.511.471.471.471.451.451.45
Market Capitalization19.7978.27128.98626.46641.20---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments11.450.100.240.15
Short Term Receivables0.760.620.743.64
Inventories7.308.126.897.33
Other Current Assets1.220.950.881.00
Total Current Assets20.739.798.7612.12
Net Property, Plant & Equipment0.701.101.311.93
Total Investments and Advances0.000.000.000.00
Intangible Assets1.121.211.301.39
Deferred Tax Assets0.200.310.37-
Other Assets0.000.000.000.00
Total Assets22.7412.4111.7515.44
Short Term Debt Incl. Current Port. of LT Debt6.9120.414.370.89
Accounts Payable2.085.293.081.39
Other Current Liabilities9.719.621.760.72
Total Current Liabilities18.7035.339.213.00
Long Term Debt0.060.525.041.07
Provision for Risks Charges0.000.000.000.00
Deferred Tax Liabilities0.200.310.37-
Other Liabilities0.000.000.670.00
Total Liabilities18.9536.1515.304.07
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.0020.2720.2720.27
Common Equity3.79-44.00-23.82-8.90
Total Shareholders Equity3.79-23.74-3.5511.37
Accumulated Minority Interest0.000.000.000.00
Total Equity3.79-23.74-3.5511.37
Total Liabilities & Stockholders Equity22.7412.4111.7515.44
Book Value Per Share2.57-30.42-322.67-6.15
Tangible Book Value Per Share1.81-31.26-340.27-7.11
Full-Time Employees7575--
Price to Book Ratio9.6416.19--
Return on Assets-153.61-174.29-114.53-
Return on Equity---398.34-
Return on Invested Capital-700.80--1,043.50-89.77
Quick Ratio0.720.050.201.60
Current Ratio1.110.280.954.04

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-27.99-27.00-21.05-15.57-11.17
Depreciation0.530.510.540.580.55
Other Funds (Non Cash)14.5614.027.671.071.83
Funds from Operations-12.90-12.47-12.84-13.91-8.80
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-3.14-3.200.963.28-1.93
Cash from Operating Activities-16.04-15.67-11.87-10.63-10.72
Capital Expenditures-0.030.000.00-0.01-0.03
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.00
Purchase of Investments0.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.00
Other Uses0.000.000.00-0.00-0.01
Other Sources0.000.000.000.000.00
Cash from Investing Activities-0.030.000.00-0.01-0.04
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock19.0817.440.002.650.00
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock19.0817.440.002.650.00
Proceedsfrom Stock Options19.0217.440.002.650.00
Issuance or Reduction of Debt, Net-3.399.6311.748.195.52
Change in Long Term Debt5.979.6311.748.195.52
Issuance of Long Term Debt14.1717.9213.129.085.55
Reduction of Long Term Debt-8.19-8.29-1.38-0.89-0.03
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities15.6927.0811.7410.845.52
Exchange Rate Effect0.01-0.05-0.01-0.100.13
Net Change in Cash-0.3711.36-0.150.09-5.10
Free Cash Flow-16.07-15.67-11.87-10.64-10.75
Preferred Dividends (Cash Flow)-0.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.040.1211.452.810.410.69
Short Term Receivables0.610.600.761.161.410.12
Inventories5.977.457.306.557.008.04
Other Current Assets0.971.351.221.060.820.93
Total Current Assets7.599.5120.7311.599.649.78
Net Property, Plant & Equipment0.490.610.700.790.891.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets1.081.101.121.151.171.19
Deferred Tax Assets--0.20---
Other Assets0.000.000.000.000.000.00
Total Assets9.1711.2222.7413.5211.7011.96
Short Term Debt Incl. Current Port. of LT Debt1.583.276.910.4421.9922.41
Accounts Payable3.322.712.083.126.375.52
Other Current Liabilities2.556.689.711.8217.2712.29
Total Current Liabilities7.4512.6618.705.3745.6440.21
Long Term Debt0.000.010.060.180.290.41
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.20---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities7.4512.6718.955.5545.9340.62
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.0020.2720.27
Common Equity1.72-1.453.797.97-54.49-48.92
Total Shareholders Equity1.72-1.453.797.97-34.23-28.66
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1.72-1.453.797.97-34.23-28.66
Total Liabilities & Stockholders Equity9.1711.2222.7413.5211.7011.96
Book Value Per Share0.83-0.962.575.41-36.97-33.82
Tangible Book Value Per Share0.31-1.691.814.63-37.76-34.64
Full-Time Employees--75--75
Price to Book Ratio9.64-54.0634.0478.62-11.77-
Return on Assets-268.26-250.68-153.61-245.79-226.29-202.39
Return on Invested Capital-329.84--111.37-127.96--
Quick Ratio0.220.160.720.940.060.04
Current Ratio1.020.751.112.160.210.24

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-5.66-7.62-4.29-10.43-6.72-5.56
Depreciation0.140.140.130.130.130.13
Other Funds (Non Cash)2.763.441.287.073.212.46
Funds from Operations-2.76-4.04-2.88-3.23-3.39-2.98
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.410.23-1.50-3.290.850.74
Cash from Operating Activities-1.35-3.80-4.38-6.51-2.54-2.24
Capital Expenditures0.00-0.030.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.030.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00---
Change in Capital Stock3.080.040.0015.961.490.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.080.040.0015.961.490.00
Proceedsfrom Stock Options3.020.040.0015.961.490.00
Issuance or Reduction of Debt, Net-1.83-7.5613.02-7.010.792.83
Change in Long Term Debt7.37-7.4013.02-7.010.792.83
Issuance of Long Term Debt0.000.0013.011.160.902.85
Reduction of Long Term Debt7.37-7.400.00-8.17-0.11-0.02
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.25-7.5213.028.952.282.83
Exchange Rate Effect0.020.02-0.00-0.03-0.01-0.00
Net Change in Cash-0.08-11.338.642.40-0.280.59
Free Cash Flow-1.35-3.83-4.38-6.51-2.54-2.24

Revenue breakdown

Product2024: 4.25M 2025: 4.75M
Rentals2024: 137.00K 2025: 194.00K
Europe2024: 991.00K 2025: 580.00K
Other Foreign Countries2024: 134.00K
United States2024: 3.27M 2025: 4.36M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.03%0.1M1.5M1.63M
2026-10-153.64%0.1M1.4M1.75M
2026-09-302.67%0.0M1.4M1.85M
2026-09-1516.44%0.2M1.4M1.87M
2026-08-3128.00%0.4M1.3M2.19M
2026-08-145.96%0.1M1.3M860.89K
2026-07-316.66%0.1M1.1M856.75K
2026-07-1527.44%0.3M1.1M757.97K
2026-06-309.89%0.1M0.7M569.34K
2026-06-1515.98%0.1M0.4M546.68K
2026-05-294.39%0.0M0.6M157.87K
2026-05-151.55%0.0M0.6M28.35K
2026-04-304.45%0.0M0.5M25.44K
2026-04-152.38%0.0M0.5M15.35K
2026-03-312.25%0.0M0.5M15.59K
2026-03-132.68%0.0M0.5M16.06K
2026-02-272.76%0.0M0.5M30.79K
2026-02-135.07%0.0M0.5M30.57K
2026-01-302.60%0.0M0.5M20.22K
2026-01-152.61%0.0M0.5M35.11K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10424B3SEC
2026-11-05S-3/ASEC
2026-11-03PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-07SEC
2026-11-038-KCurrent report2026-10-28SEC
2026-10-238-KCurrent report2026-10-20SEC
2026-10-22S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-138-KCurrent report2026-10-07SEC
2026-10-068-KCurrent report2026-09-30SEC
2026-08-208-KCurrent report2026-08-19SEC
2026-08-1910-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-17NT 10-Q2026-06-30SEC
2026-08-07SCHEDULE 13G/ASEC
2026-07-278-KCurrent report2026-07-22SEC
2026-07-228-KCurrent report2026-07-21SEC
2026-07-218-KCurrent report2026-07-17SEC
2026-07-16DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-138-K/A2026-07-02SEC
2026-07-08DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-078-K/A2026-06-23SEC
2026-07-02425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-028-KCurrent report2026-07-02SEC
2026-07-02425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-028-KCurrent report2026-07-02SEC
2026-06-298-KCurrent report2026-06-23SEC
2026-06-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-17SEC
2026-06-248-KCurrent report2026-06-18SEC
2026-06-15PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-17SEC
2026-06-05SCHEDULE 13G/ASEC
2026-06-03144Filing for proposed sale of securities under Rule 144.SEC
2026-06-028-KCurrent report2026-06-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC2.73%
AQR CAPITAL MANAGEMENT LLC2.32%
JANE STREET GROUP, LLC1.49%
IEQ CAPITAL, LLC0.31%
UBS Group AG0.22%
RENAISSANCE TECHNOLOGIES LLC0.19%
Cerity Partners LLC0.13%
Mariner, LLC0.08%
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC0.08%
Hudson Bay Capital Management LP0.07%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.73%
WisdomTree International SmallCap Dividend Fund0.66%
WisdomTree Dynamic International SmallCap Equity Fund0.23%
WisdomTree Europe SmallCap Dividend Fund0.20%
Fidelity Small Cap Index Fund0.06%
VANGUARD RUSSELL 2000 INDEX FUND0.03%
Schwab Small-Cap Index Fund0.02%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND0.01%
Victory Extended Market Index Fund0.00%
Global X Russell 2000 ETF0.00%

OakChart. PMI. Cached 15 minutes.